Exchange: NASDAQ·Updated 07:00 AM EDT
News
all
press releases
Enanta Pharmaceuticals (ENTA) Reports Q3 Loss, Lags Revenue Estimates
Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of -81.08% and -20.97%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
More News
Regenxbio (RGNX) Beats Q2 Earnings and Revenue Estimates
Regenxbio (RGNX) delivered earnings and revenue surprises of +258.33% and +16.31%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Editas Medicine (EDIT) Reports Q2 Loss, Beats Revenue Estimates
Editas (EDIT) delivered earnings and revenue surprises of +50.00% and +524.80%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Travere Therapeutics (TVTX) Reports Q2 Loss, Beats Revenue Estimates
Travere (TVTX) delivered earnings and revenue surprises of -164.29% and +10.16%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Krystal Biotech, Inc. (KRYS) Q2 Earnings and Revenues Beat Estimates
Krystal Biotech (KRYS) delivered earnings and revenue surprises of +5.29% and +0.14%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
RenovoRx (RNXT) Q1 2026 Earnings Transcript
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...
Nasdaq News: Markets
RenovoRx, Inc. (RNXT) Reports Q1 Loss, Tops Revenue Estimates
RenovoRx (RNXT) delivered earnings and revenue surprises of 0.00% and +12.60%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Amphastar Pharmaceuticals (AMPH) Q1 Earnings Lag Estimates
Amphastar (AMPH) delivered earnings and revenue surprises of -40.28% and +0.27%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
RenovoRx, Inc. (RNXT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
RenovoRx (RNXT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
Tenaya Therapeutics, Inc. (TNYA) Reports Q1 Loss, Misses Revenue Estimates
Tenaya Therapeutics (TNYA) delivered earnings and revenue surprises of +4.26% and -97.75%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks

Advertisement|Remove ads.